All AbMole products are for research use only, cannot be used for human consumption.
For this product's availability, delivery time and price, please email inquiry@abmole.com directly or click the "Inquiry Now" button below.
Lucerasta is the galactose form of Miglustat, an orally active inhibitor of glucosylceramide synthase (GCS).Lucerastat has potential for use in Fabry disease research.
| Molecular Weight | 219.28 |
| Formula | C10H21NO4 |
| CAS Number | 141206-42-0 |
| Storage | -20°C, dry, sealed |
[1] Frank Weidemann, et al. Int J Mol Sci. Chaperone Therapy in Fabry Disease
[2] Malte Lenders, et al. Drugs. Fabry Disease: The Current Treatment Landscape
[4] M Michaud, et al. Rev Med Interne. [Fabry disease: A review]
[5] Sanne J van der Veen, et al. J Inherit Metab Dis. Developments in the treatment of Fabry disease
| Related Glucosylceramide Synthase Products |
|---|
| Eliglustat
Eliglustat inhibits glucosylceramide synthase (GCS), thus reducing the load of glucosylceramide influx into the lysosome. |
| Miglustat
Miglustat(OGT918) is an inhibitor of glucosylceramide synthase, primarily to treat Type I Gaucher disease (GD1). |
| Ibiglustat
Ibiglustat (Venglustat) is a potent and selective Glucosylceramide synthase inhibitor and ceramide glucosyltransferase inhibitor. |
| Miglustat hydrochloride
Miglustat hydrochloride also known as OGT 918 and NB-DNJ, inhibits glucosylceramide synthase, and is used primarily to treat Type I Gaucher disease (GD1). |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.
